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Abstract: We report herein the straightforward two-step synthesis and biological assessment of
novel racemic benzochromenopyrimidinones as non-hepatotoxic, acetylcholinesterase inhibitors
with antioxidative properties. Among them, compound 3Bb displayed a mixed-type inhibition of
human acetylcholinesterase (IC50 = 1.28 ˘ 0.03 µM), good antioxidant activity, and also proved to be
non-hepatotoxic on human HepG2 cell line.
Keywords: Alzheimer’s disease; quinazolinones; multicomponent reactions; multitarget-directed
ligands; antioxidants; cholinesterase inhibitors; hepatotoxicity
1. Introduction
Alzheimer’s disease (AD) has emerged as the main cause of memory and cognitive deficiency in
aged persons. The Alzheimer’s disease International (ADI) Association report from 2015 estimates
that over 46 million people are currently affected by dementia. Given the epidemic expansion of
AD, this number is expected to drastically increase in the future, reaching 131.5 million cases by
2050 [1]. Many efforts have been devoted to comprehend the complex etiology of AD, yet certain
aspects of the pathogenesis are still not well understood. Nevertheless, several histopathologic
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features have been clearly identified in AD patients such as intracellular neurofibrillary tangles,
composed of hyperphosphorylated tau protein and toxic amyloid plaques of aggregated β-amyloid
(Aβ) peptide. Moreover, different levels of neuronal loss have been observed in the Locus coeruleus [2],
Nucleus basalis [3] and Substantia nigra [4] brain areas, leading to substantial perturbations in
several neurotransmission systems such as the cholinergic, serotoninergic, GABAergic, glutamatergic,
noradrenergic or dopaminergic system.
Oxidative stress holds a fundamental position in the onset and development of AD. Several
studies have confirmed that the constant accumulation of reactive oxygen species and reactive nitrogen
species leads inevitably to serious oxidative damage in neuronal tissues [5]. This oxidative stress
can be triggered by different underlying factors such as mitochondrial dysfunction [6], loss of metal
homeostasis (e.g., Cu2+, Fe2+, Zn2+), the involvement of the later ions in Aβ aggregation [7], and
neuroinflammation [8]. Globally, there is unanimity to consider these different biological events all at
once, and address the unmet need for an efficient anti-AD agent.
In terms of medication use, the currently marketed drugs are mainly inhibitors of cholinesterases
(ChEIs) (acetylcholinesterase, AChE; and butyrylcholinesterase, BuChE). These are donepezil,
rivastigmine, and galantamine [9], which enhance the levels of neurotransmitter acetylcholine in the
synaptic cleft. The only drug with a different mechanism of action is memantine, a N-methyl-D-aspartate
receptor antagonist [10]. One of the first marketed ChEI, tacrine, was rapidly withdrawn, principally
because of its hepatotoxicity [11]. Globally, the therapeutic efficacy of pure ChEIs may be brought
into question since only scarce improvements in memory and cognitive functions have been
reached in AD patients, with no signs of clear reversal of the disease. Therefore, the design of new
multitarget-directed ligands represents one of the most promising approaches for the development of
new disease-modifying agents for AD therapy [12–14]. Indeed, compounds capable to simultaneously
modulate various biological systems in relation with AD pathogenesis might be a winning strategy in
the future by furnishing fine-tuned drug candidates for the clinics.
Several series of quinazolinone derivatives have already been developed, inspired by naturally
occurring alkaloids deoxyvasicinone (Ia), dehydroevodiamine chloride (II), evodiamine (III) and
rutaecarpine (IV) (Figure 1), with promising inhibition of ChEs [15–17]. Further SAR investigations
were done and revealed that some new carbamate analogues of evodiamine were selective
butyrylcholinesterase inhibitors (BuChEIs), potent antioxidants and neuroprotective agents against
glutamate-induced oxidative stress in HT-22 cells [16].
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In relation with these antecedents and with our earlier work [18,19], we applied a multicomponent
reaction approach to further explore the chemical space based on the quinazolinone scaffold. Thus, we
have designed new benzochromenopyrimidinones of type V and VI (abbreviated as BCPOs, Figure 1),
Molecules 2016, 21, 634 3 of 15
where a benzochromene motif was fused to the pyrimidinone motif present in alkaloids Ia–IV. As
a result, eighteen new BCPOs were synthesized and evaluated for their antioxidant activity, ChE
inhibition, and their in vitro toxicity in liver HepG2. From these studies, we have identified compound
3Bb as a promising derivative potentially useful in further AD drug discovery steps.
2. Results and Discussion
2.1. Synthesis
The synthesis of the target BCPOs 3 and 4 has been carried out in two steps, and good overall yields as
outlined in Scheme 1. First, a microwave-assisted multicomponent reaction of ethyl cyanoacetate, selected
aromatic aldehydes, and 2- or 1-naphthol, in the presence of a catalytic amount of piperidine in ethanol,
at 80 ˝C, for 10 min, gave the corresponding ethyl 3-amino-1-phenyl-1H-benzo[f ]chromene-2-carboxylates
1A–C or ethyl 2-amino-4-phenyl-4H-benzo[h]chromene-3-carboxylates 2A–C, respectively, in good
yields (68%–90%). The second step was the condensation of adducts 1A–C or 2A–C with the
appropriate commercial lactams, in the presence of phosphorus oxytrichloride in 1,2-dichloroethane,
under microwave irradiation for 15 min at 80 ˝C, to give compounds 3 and 4 in high yields
(70%–96%). All new compounds displayed satisfactory analytical and spectroscopic data correlating
with their structure, and with the data reported in the literature for comparable molecules
(see Experimental Section).
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2.2. Evaluation of the Antioxidant Power
First of all, we evaluated the antioxidant activity of compounds 3 and 4 using the oxygen
radical absorbance capacity by fluorescence (ORAC-FL) method [20,21]. Trolox was used as standard,
fluorescein as fluorescent probe and 2,21-azobis(2-amidinopropane) dihydrochloride (AAPH) as the
peroxyl radical source. Ferulic acid was used as a positive control [22]. Data were expressed as Trolox
equivalents (TE), and as shown in table 1, all compounds were able to scavenge the peroxyl radical
with ORAC values ranging between 2.3 and 4.7 TE. The unsubstituted adducts 3Aa–c, 4Aa–c were
found to be slightly less potent than the analogues bearing methoxy and methyl groups at the aromatic
ring, with values ranging between 2.1 and 2.6 TE. However, when the phenyl moiety was substituted
by a methoxy group, we globally observed a better antioxidant activity, compound 3Bb being the most
active (4.7 TE) and displaying enhanced antioxidant activity compared to ferulic acid (3.7 TE).
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2.3. Evaluation of AChE and BuChE Inhibition
For the preliminary screening of the inhibitory potencies, Electrophorus electricus AChE (EeAChE)
and horse serum BuChE (eqBuChE) were used following the Ellman’s assay [23]. Tacrine, able to inhibit
both ChEs, was selected as a control. First of all, compounds 3 and 4 were poor eqBuChEIs, and due to
the limited solubility in the assay medium, only the percentage of inhibition at 10 µM was determined.
However, these compounds exhibited encouraging inhibitory potencies against EeAChE with IC50
values ranging from 30.5 to 518.4 nM. The most potent EeAChEIs, in decreasing order, were compounds
3Bb, 3Ab, 3Cb and 3Ba with IC50 30.5, 55.5, 55.9 and 60.7 nM values, respectively, showing activities
comparable to that of tacrine (IC50 = 44.3 nM). Very interestingly, and for comparative purposes,
related natural alkaloids Ia [24] or II [15], and synthetic compounds Ib,c [24] are poorer EeAChEIs
than BCPOs 3 and 4 (Table 1).
Table 1. Inhibitions of EeAChE, eqBuChE, hAChE and ORAC-FL values for compounds 3 and 4.
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When examining the structure-activity relationships (SAR), we could observe that the four most
active compounds (3Ab, 3Bb, 3Cb and 3Ba) belong to the V family (Figure 1). Concerning the size
of the saturat d carbocyclic ring attached to the pyrimidinone moiety and considering the same
substituent on the ar matic ring attached at the ster og nic c nt r, the ost potent ACh Is were
compounds bearing a piperidine-fused ring (3Ab, 3Bb, and 3Cb) for the V family. For the VI type
derivatives, no evident SAR could have been established. Finally, we can notice that BCPOs of type V,
with a methoxy-substituted benzene ring had IC50 values for the inhibition of EeAChE much higher
than non-substituted analogues.
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Based on these findings, we selected compounds 3Ab, 3Bb, 3Cb and 3Ba for the Aβ1–42
aggregation inhibition studies. Unfortunately, only compound 3Ab showed a weak inhibition power
(Supplementary Materials). Next, we investigated the ability of compounds 3Ab, 3Bb, 3Cb and 3Ba to
inhibit human recombinant AChE (hAChE), and their liver toxicity.
2.4. Kinetic Study of the hAChE Inhibition by Compound 3Bb
As shown in Table 1, we found significantly lower inhibition for hAChE in comparison with
EeAChE, the IC50 values ranging from 1279 to 3657 nM. Compound 3Bb was the most potent inhibitor
with an IC50 value of 1279 nM.
To get insight into the mode of inhibition, the kinetic mechanism of hAChE inhibition by
compound 3Bb was investigated through classical Lineweaver-Burk double reciprocal plots. Analysis
of this plot (Figure 2) showed the interception of the lines above the x-axis indicating that 3Bb is able
to interact with both the free and acylated enzyme, and therefore behaves as mixed-type inhibitor
of hAChE. The inhibitor dissociation constants Ki (dissociation constant for the enzyme-inhibitor
complex) and K’i (dissociation constant for the enzyme-inhibitor-substrate complex) were estimated
and were 0.38 and 1.12 µM, respectively.
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Figure 2. Lineweaver–Burk double reciprocal plot demonstrating mixed-type of hAChE inhibition by
compound 3Bb. S = acetylthiocholine; V = initial velocity rate.
2.5. In Vitro Toxicity of Compounds 3Ab, 3Bb, 3Cb and 3Ba in HepG2 Cells
A prerequisite for any effective lead drug is to keep its cytotoxicity at the lowest possible level. In
this regard, we submitted the four most promising compounds (3Ab, 3Bb, 3Cb and 3Ba) to an in vitro
toxicologic evaluation (MTT assay) using human hepatocellular carcinoma cell line (HepG2) which
represents a good probe to evaluate hepatotoxic effects. As shown in Table 2, tacrine was safe up to
100 µM but significantly decreased cell viability above 300 µM. The four tested BCPOs had no toxic
effects on the HepG2 cells (Table 2) measured in concentrations up to 1000 µM [25] and could therefore
be considered as non-hepatotoxic.
Table 2. In vitro toxicity (% cell viability) of selected 3Ab, 3Bb, 3Cb and 3Ba and tacrine in HepG2 cells.
BCPO 1 µM 3 µM 10 µM 30 µM 100 µM 300 µM 1 mM
3Ab 99.3 ˘ 4.0 95.3 ˘ 2.3 98.5 ˘ 2.5 91.5 ˘ 4.5 100.8 ˘ 3.1 110.5 ˘ 5.5 110.4 ˘ 4.4
3Bb 107.7 ˘ 2.4 111.1 ˘ 8.7 104.7 ˘ 4.2 104.1 ˘ 5.0 111.8 ˘ 2.3 118.0 ˘ 7.3 127.8 ˘ 5.0
3Cb 105.8 ˘ 7.0 102.9 ˘ 10.8 110.2 ˘ 9.1 112.7 ˘ 5.8 103.1 ˘ 5.7 113.0 ˘ 5.2 110.2 ˘ 8.0
3Ba 108.6 ˘ 2.0 107.7 ˘ 4.8 106.2 ˘ 3.5 99.2 ˘ 4.2 97.0 ˘ 5.4 107.6 ˘ 2.8 119.5 ˘ 6.8
acrine 105. ˘ 4. 103.5 ˘ 8.7 97.0 ˘ 6.5 93.0 ˘ 2.7 95.2 ˘ 6.0 47.6 ˘ 5.6 *** 13.9 ˘ 0.8 ***
Means ˘ SEM of triplicates at least hree different cultures. *** p < 0.001, as compared to the control
cultures (one-way ANOVA).
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2.6. Blood Brain Barrier Penetration PAMPA Assay
Prediction of blood-brain barrier (BBB) penetration is summarized in Table 3. Compound 3Ab
showed the highest probability to cross the BBB via passive diffusion. Compound 3Ba seems to be
also central nervous systems (CNS) available according to the results obtained, however Pe value
is on the lower limit for permeable compounds. Compounds 3Bb and 3Cb were not satisfactorily
distinguished. Whereas Pe value for the compound 3Bb fails into the uncertain interval, the value for
the compound 3Cb was not determined due to the low solubility of the compound and therefore low
UV/Vis absorption.
Table 3. Prediction of BBB penetration of drugs expressed as Pe ˘ SEM (n = 6–8).
Compound BBB Penetration Estimation
Pe ˘ SEM (ˆ10´6 cm s´1) CNS (+/´)
3Ab 7.2 ˘ 0.6 CNS (+)
3Bb 3.6 ˘ 0.57 CNS (+/´)
3Cb ND *
3Ba 4.6 ˘ 0.77 CNS (+)
Donepezil 7.3 ˘ 0.9 CNS (+)
Rivastigmine 6.6 ˘ 0.5 CNS (+)
Tacrine 5.3 ˘ 0.19 CNS (+)
Testosterone 11.3 ˘ 1.6 CNS (+)
Chlorpromazine 5.6 ˘ 0.6 CNS (+)
Hydrocortisone 2.85 ˘ 0.1 CNS (+/´)
Piroxicam 2.2 ˘ 0.15 CNS (+/´)
Theophyline 1.07 ˘ 0.18 CNS (´)
Atenolol 1.02 ˘ 0.37 CNS (´)
‘CNS (+)’ (high BBB permeability predicted); Pe (10´6 cm¨ s´1) > 4.0. ‘CNS (´) (low BBB permeability
predicted); Pe (10´6 cm¨ s´1) < 2.0. ‘CNS (+/´) (BBB permeability uncertain); Pe (10´6 cm¨ s´1) from 4.0 to 2.0.
* Not Determined due to a low solubility; CNS (+)=
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distinguished. Whereas Pe value for the compound 3Bb fails into the uncertain interval, the value for 
the compound 3Cb was not determined due to the low solubility of the compound and therefore low 
UV/Vis absorption. 
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CNS availability is known and also reported using the PAMPA assay [26,27]. Our data show high 
resemblance with previously reported results as well as with a general knowledge about the CNS 
availability for these drugs. 
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Rivastigmine 6.6 ± 0.5 CNS (+) 
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Chlorpromazine 5.6 ± 0.6 CNS (+) 
Hydrocortisone 2.85 ± 0.1 CNS (+/−)
Piroxicam 2.2 ± 0.15 CNS (+/−)
Theophyline 1.07 ± 0.18 CNS (−) 
Atenolol 1.02 ± .37 CNS (−) 
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Melting points were determined on a Kofler apparatus (Wagner Munz, München, Germany), 
and are uncorrected. Progress of the reactions was monitored with TLC using aluminium sheets with 
silica gel 60 F254 from Merck (Kenilworth, NJ, USA). IR spectra were recorded on a PARAGON FT-IR 
spectrometer (Perkin-Elmer, Waltham, MA, USA) covering field 400–4000 cm−1. 1H-NMR and 13C-NMR 
were recorded on a Bruker spectrometer (Bruker BioSpin, Fällanden, Switzerland) (1H-NMR at 300 MHz, 
13C-NMR at 75 MHz) using CDCl3 or DMSO-d6 as solvents. The chemical shifts are reported in parts per 
million (ppm), using tetramethylsilane (TMS) as internal reference. The multiplicities of the signals are 
indicated by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quadruplet; and m, 
multiplet coupling constants are expressed in Hz. Elemental analysis were performed on Flash EA 1112 
Thermo Finnigan, (Thermo scientific, Waltham, MA, USA). The microwave assisted reactions were 
carried out in synthesis microwave (Anton Paar 300, Peseux, Switzerland) with a maximum power 
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also central nervous systems (CNS) available ac ording to the results obtained, however Pe value is 
on the lower limit for permeable compounds. Compounds 3Bb and 3Cb were not satisfactorily 
distinguished. Whereas Pe value for the compound 3Bb fails into the uncertain interval, the value for 
the compound 3Cb was not determined due to the low solubil ty of the compound and therefore low 
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Data obtained for the new compounds cor elate wel  with values for controls drugs, where 
CNS availabil ty is known and also reported using the PAMPA as ay [26,27]. Our data show high 
resemblance with previously reported results as wel  as with a general knowledge about the CNS 
availability for these drugs. 
Table 3. Prediction of B  penetration of drugs expres ed as Pe ± SEM (  = 6–8). 
Compound 
B  Penetration Estimation
Pe ± SEM (×10−6 cm s−1) CNS (+/−)
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3Bb 3.6 ± 0.57 CNS (+/−)
3Cb ND *  
3Ba 4.6 ± 0.7  CNS (+) 
Donepezil 7.3 ± 0.9 CNS (+) 
Rivastigmine 6.6 ± 0.5 CNS (+) 
Tacrine 5.3 ± 0.19 CNS (+) 
Testosterone 1 .3 ± 1.6 CNS (+) 
Chlorpromazine 5.6 ± 0.6 CNS (+) 
Hydrocortisone 2.85 ± 0.1 CNS (+/−)
Piroxicam 2.2 ± 0.15 CNS (+/−)
Theophyline 1.07 ± 0.18 CNS (−) 
Atenolol 1.02 ± 0.37 CNS (−) 
‘CNS (+)’ (high B  permeabil ty predicted); Pe (10−6 cm·s−1) > 4.0. ‘CNS (−) (low B  permeabil ty 
predicted); Pe (10−6 cm·s−1) < 2.0. ‘CNS (+/−) (B  permeabil ty uncertain); Pe (10−6 cm·s−1) from 4.0 to 
2.0. * Not Determined due to a low solubil ty; CNS (+)= ; CNS (+/−)= ; CNS (−)= . 
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CNS availability is known and also reported using the PAMPA assay [26,27]. Our data show high
resemblance with previously reported results as well as with a general knowledge about the CNS
availability for these drugs.
3. Materials and Methods
3.1. Chemistry Methods
Melting points were determined on a Kofler apparatus (Wagner Munz, München, Germany),
and are uncorrected. Progress of the reactions was monitored with TLC using aluminium sheets
with silica gel 60 F254 from Merck (Kenilworth, NJ, USA). IR spectra were recorded on a PARAGON
FT-IR spectrometer (Perkin-Elmer, Waltham, MA, USA) covering field 400–4000 cm´1. 1H-NMR
and 13C-NMR were recorded on a Bruker spectrometer (Bruker BioSpin, Fällanden, Switzerland)
(1H-NMR at 300 MHz, 13C-NMR at 75 MHz) using CDCl3 or DMSO-d6 as solvents. The chemical
shifts are reported in parts per million (ppm), using tetramethylsilane (TMS) as internal reference.
The multiplicities of the signals are indicated by the following abbreviations: s, singlet; d, doublet;
t, triplet; q, quadruplet; and m, multiplet coupling constants are expressed in Hz. Elemental analysis
were performed on Flash EA 1112 Thermo Finnigan, (Thermo scientific, Waltham, MA, USA). The
microwave assisted reactions were carried out in synthesis microwave (Anton Paar 300, Peseux,
Switzerland) with a maximum power of 300 W.
3.1.1. General Procedure for the Compounds 1A–C and 2A–C
A mixture of appropriate aromatic aldehyde (0.01 mol), ethyl cyanoacetate (0.01 mol), 1-naphthol
(or 2-naphthol) (0.01 mol) in ethanol (20 mL) in the presence of piperidine (0.2 equiv) was irradiated
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for 10 min in a sealed tube. The irradiation was programed to maintain a constant temperature
(80 ˝C, 150 W). The obtained precipitate was filtered, washed with cold ethanol and dried, to give the
desired compounds.
Ethyl 3-amino-1-phenyl-1H-benzo[f]chromene-2-carboxylate (1A) [27]: Yield 90%; mp 168–170 ˝C; IR (KBr)
νmax 3300–3438, 1685 cm´1; 1H-NMR (DMSO-d6) 1.23–1.28 (m, 3H), 4.08–4.17 (m, 2H), 5.51 (s, 1H),
7.00–8.02 (m, 11H, arom.), 7.67 (s, 2H, NH2); 13C-NMR (DMSO-d6) 14.9, 37.0, 59.3, 78.2, 117.2, 119.3,
123.6, 125.2, 126.4, 127.5, 128.2, 128.5, 129.0, 129.4, 130.7, 131.2, 147.2, 147.3, 160.9, 168.6.
Ethyl 3-amino-1-(3-methoxyphenyl)-1H-benzo[f]chromene-2-carboxylate (1B): Yield 73%; mp 168–170 ˝C;
IR (KBr) νmax 3339–3425, 1690 cm´1; 1H-NMR (DMSO-d6) 1.14–1.20 (m, 3H), 3.80 (s, 3H), 4.01–4.12
(m, 2H), 5.82 (s, 1H), 6.72–8.25 (m, 10H, arom.), 7.68 (s, 2H, NH2); 13C-NMR (DMSO-d6) 14.7, 31.3, 55.8,
59.1, 77.5, 111.6,117.1, 119.5, 120.8, 123.7, 125.0, 127.3, 127.7, 128.9, 128.9, 130.5, 131.0, 131.3, 135.5, 147.3,
156.1, 161.4, 169.0.
Ethyl 3-amino-1-p-methylphenyl-1H-benzo[f]chromene-2-carboxylate (1C) [28]: Yield 75%; mp 194–196 ˝C;
IR (KBr) νmax 3320–3440 (NH2), 1687 (CO) cm´1; 1H-NMR (DMSO-d6) 1.24–1.31 (m, 3H), 2.10 (s, 3H),
4.09–4.23 (m, 2H), 5.49 (s, 1H), 6.93–8.01 (m, 10H, arom.), 7.68 (s, 2H, NH2); 13C-NMR (DMSO-d6) 14.9,
20.9, 36.6, 59.3, 78.3, 117.1, 119.4, 123.6, 125.2, 127.4, 128.0, 129.0, 129.1, 129.3, 130.8, 131.2, 135.3, 144.4,
147.2, 160.9, 168.7.
Ethyl 2-amino-4-phenyl-4H-benzo[h]chromene-3-carboxylate (2A) [29]: Yield 88%; mp 160-162 ˝C; IR (KBr)
νmax 3372–3260, 1692 cm´1; 1H-NMR (DMSO-d6) 1.10–1.18 (m, 3H), 4.01–4.11 (m, 2H), 5.04 (s, 1H),
7.04–8.33 (m, 11H, arom.), 7.64 (s, 2H, NH2); 13C-NMR (DMSO-d6) 14.7, 40.5, 59.0, 76.8, 121.1, 121.4,
123.2, 124.1, 126.4, 126.9, 126.9, 127.0, 127.7, 128.1, 128.6, 132.9, 143.2, 148.2, 161.2, 168.7.
Ethyl 2-amino-4-m-methoxyphényl-4H-benzo[h] chromene-3-carboxylate (2B): Yield 75%; mp 156–158 ˝C;
IR (KBr) νmax 3393–3280, 1663 cm´1; 1H-NMR (DMSO-d6) 1.09–1.18 (m, 3H), 3.68 (s, 3H), 4.02–4.14
(m, 2H), 5.01 (s, 1H), 6.67–8.32 (m, 10H, arom.), 7.63 (s, 2H, NH2); 13C-NMR (DMSO- d6) 14.2, 40.0,
54.8, 58.6, 76.2, 110.7, 113.5, 119.5, 120.6, 120.8, 122.7, 123.6, 126.4, 126.4, 126.5, 127.6,129.2, 132.4, 142.8,
149.3, 159.0, 160.8, 168.2.
Ethyl-2-amino-4-p-methylphenyl-4H-benzo[h]chromene-3-carboxylate (2C) [29]: Yield 68%; mp 158–160 ˝C;
IR (KBr) νmax 3315–3452, 1672 cm´1; 1H-NMR (DMSO-d6) 1.10–1.17 (m, 3H), 2.28 (s, 3H), 4.00–4.09
(m, 2H), 4.98 (s, 1H), 6.98–8.29 (m, 10H, arom.), 7.62 (s, 2H, NH2); 13C-NMR (DMSO-d6) 14.7, 20.9,
40.8, 59.0, 76.9, 121.2, 121.8, 123.3, 124.1, 126.8, 126.9, 127.0, 127.6, 128.0, 129.2,132.9, 135.4, 143.2, 145.3,
161.2, 168.7.
3.1.2. General Procedure for the Synthesis of Benzochromenopyrimidinones (BCPOs)
POCl3 (0.14 mL, 0.23 g, 1.5 equiv) was added dropwise to a mixture of the corresponding ethyl
aminobenzochromene-2-carboxylate and the appropriate lactam (1.5 equiv) in 1,2-dichloroethane
(20 mL). After microwave irradiation, approximately 80% of the solvent was evaporated and water
(10 mL) was added. The solution was basified with 20% aqueous NaOH, then the mixture was extracted
with CH2Cl2, washed with water (20 mL), and dried over MgSO4. The solvent was evaporated, the
solid obtained was washed with ether and filtered to give benzochromenopyrimidinones 3 and 4.
14-Phenyl-10,11-dihydro-14H-benzo[5,6]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-13(9H)-one (3Aa): Yield
80%; mp > 260 ˝C; IR (KBr) νmax 1667, 1587 cm´1; 1H-NMR (CDCl3) 2.18–2.22 (m, 2H, H10), 2.28–2.36
(m, 2H, H9), 3.20–3.29 (m, 2H, H11), 5.31 (s, 1H, H14), 6.64 (d, J = 7.8 Hz 1H, H6), 7.19–7.48 (m, 7H,
H2, H3, H21,H51,H31,H61,H41), 7.80 (d, J = 8.1 Hz, 2H, H4, H5), 7.96 (d, J = 8.4 Hz,1H,H1); 13C-NMR
(CDCl3) 18.6 (CH2, C10), 32.0 (CH2, C9), 36.0 (CH, C14), 46.6 (CH, C11), 100.8 (C, C13a), 115.9 (CH,
C6), 116.9 (CH, C1), 123.1 (CH, C3), 124.4 (CH, C2), 126.1 (CH, C4), 126.3 (CH, C5), 126.6 (CH, C41),
127.8 (2 CH, C21, C61), 127.9 (2 CH, C31, C51), 128.8 (C, C14b), 130.6 (C, C14a), 131.0 (C, C4a), 143.3
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(C, C11), 147.8 (C, C6a), 160.5 (C, C8a), 160.9 (C, C7a), 162.1 (C, C13). Anal. Calcd. for C24H18N2O2:
C, 78.67; H, 4.95; N, 7.65. Found: C, 78.61; H, 4.98; N, 7.69.
15-Phenyl-10,11,12,15-tetrahydro-9H-benzo[5,6]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-14-one (3Ab): Yield
96%; mp 236 ˝C; IR (KBr) νmax 1669, 1587 cm´1; 1H-NMR (CDCl3) 1.83–1.94 (m, 4H, H11, H10),
2.91–2.94 (m,H9, 2H), 3.87–3.93 (m, H12, 2H), 5.76 (s, H15, 1H), 7.07 (d, J = 7.8 Hz, H6, 1H), 7.16–7.52
(m, H2, H3, H5, H21,H51,H31,H61,H41, 8H), 7.97 d (J = 8.4 Hz, H1, H4, 2H); 13C-NMR (CDCl3) 18.2
(CH2, C10), 20.9 (CH2, C11), 30.9 (CH2, C9), 35.9 (CH, C15), 42.4 (CH, C12), 99.6 (CH, C14a), 116.4
(C, C6), 117.3 (CH, C1), 123.3 (CH, C3), 124.9 (CH, C2), 126.4 (CH, C4), 127.1 (CH, C5), 128.1 (CH,C41),
128.2 (2 CH, C21, C61), 128.5 (2 CH, C31, C51), 129.4 (C, C15b), 130.4 (C, C15a), 130.9 (C, C4a), 144.2
(C, C11), 147.7 (C, C6a), 158.9 (C, C8a), 159.4 (C, C7a), 161.4 (C,C14). Anal. Calcd. for C25H20N2O2:
C, 78.93; H, 5.30; N, 7.36. Found: C, 78.92; H, 5.32; N, 7.32.
16-Phenyl-10,11,12,13,-tetrahydro-16H-benzo[5,6]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-15(9H)-one (3Ac):
Yield 85%; mp 242 ˝C; IR (KBr) νmax 1660, 1589 cm´1; 1H-NMR (CDCl3) 1.78–1.83 (m, H12, H11, H10,
H9, 8H), 2.97–2.99 (m, H13, 2H), 5.89 (s, H16, 1H), 7.09 d (J = 7.8 Hz, H6, 1H), 7.19–7.48 m (m, H2,
H3, H21, H51, H31, H61,H4, 7H), 7.81 (d, J = 8.1 Hz, H4, H5, 2H), 7.96 (d, J = 8.4 Hz,H1, 1H); 13C-NMR
(CDCl3) 24.0 (CH2,C10), 26.7 (CH2,C11), 29.1 (CH2, C12), 36.4 (CH2,C16), 36.8 (CH, C9), 42.6 (CH, C13),
100.6 (CH,C15a), 116.2 (C,C6), 117.0 (CH, C1), 123.2 (CH,C3), 124.3(CH,C2), 126.0 (CH,C4), 126.5
(CH, C5), 127.9 (2 CH, C21, C61), 128.0 (2 CH, C31, C51), 128.4 (CH, C41), 128.7 (C, C16b), 130.6 (C, C16a),
130.9 (C, C4a), 143.4 (C, C11), 147.7 (C, C6a), 158.8 (C, C8a), 161.6 (C, C7a), 162.5 (C, C15). Anal. Calcd.
for C26H22N2O2: C, 79.17; H, 5.62; N, 7.10. Found: C, 79.25; H, 5.60; N, 7.17.
14-(31Methoxyphenyl)-10,11-dihydro-14H-benzo[5,6]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-13(9H)-one (3Ba):
Yield 81%; mp 211 ˝C; IR (KBr) νmax1660, 1591cm´1; 1H-NMR (CDCl3) 2.22–2.27 (m, H10, 2H),
3.01–3.14 (m, H9, 2H), 3.71 (s, OCH3, 3H), 4.13–4.17 (m, H11, 2H), 5.92 (s, H14, 1H), 6.66 (d, J = 7.8 Hz,
H6, 1H), 6.99–7.48 (m, H2, H3, H21,H51, H61, H41, 6H), 7.82 (d, J = 8.4 Hz, H4, H5, 2H), 7.99 (d,
J = 8.1 Hz, H1, 1H); 13C-NMR (CDCl3) 18.6 (CH, C10), 31.9 (CH, C9), 35.9 (CH, C14), 46.5 (CH, C11),
55.0 (OCH3), 100.7 (C, C13a), 111.3 (CH, C41), 114.0 (CH, C21), 115.9 (CH,C5), 116.9 (CH,C61), 120.4
(C, C14a), 123.1 (CH, C1), 124.4 (CH, C3), 126.5 (CH, C2), 127.9 (CH, C6), 128.7 (CH, C4), 128.8 (C, C4a),
130.6 (CH, C51), 131.0 (C, C14b), 144.9 (C, C11), 147.8 (C, C6a), 158.1 (C, C8a), 160.6 (C, C7a), 161.0
(C, C13), 162.0 (C, C31). Anal. Calcd. for C25H20N2O3: C, 75.74; H, 5.09; N, 7.07. Found: C, 75.69;
H, 5.12; N, 7.11.
15-(31-Methoxyphenyl)-10,11,12,15-tetrahydro-9H-benzo[5,6]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-14-one
(3Bb): Yield 90%; mp 212 ˝C; IR (KBr) νmax 1658, 1583 cm´1; 1H-NMR (CDCl3) 1.85–1.94 (m, H9, H10,
H11, 6H), 2.86–2.94 (m, H12, 2H), 3.71 (s, OCH3, 3H), 5.89 (s, H15, 1H), 6.65 (d, J = 7.8 Hz, H6, 1H),
6.99–7.46 (m, H2, H3, H21, H51, H61, H41, 6H), 7.80 (d, J = 8.4 Hz, H4, H5, 2H), 7.98 (d, J = 8.1 Hz,H1,
1H); 13C-NMR (CDCl3) 19.0 (CH,C10), 21.8 (CH, C11), 31.5 (CH, C9), 36.6 (CH, C15), 42.9 (CH, C12),
55.0 (C, OCH3), 100.8 (C,C14a), 114.6 (CH, C21), 116.6 (CH, C5), 117.1 (CH, C41), 117.5 (CH, C61),
121.0 (C, C15a), 123.7 (CH, C1), 124.8 (CH, C3), 127.0 (CH, C2), 128.4 (CH, C6), 129.1 (CH, C4), 129.3
(C, C4a), 131.0 (C, C15b), 131.2 (CH, C51), 145.5 (C, C11), 148.2 (C, C6a), 158.5 (C,C8a), 159.0 (C, C7a),
159.5 (C, C14), 162.4 (C, C31). Anal. Calcd. or C26H22N2O3: C, 76.08; H, 5.40; N, 6.82. Found: C, 76.13;
H, 5.36; N, 6.85.
16-(31-Methoxyphenyl)-10,11,12,13-tetrahydro-16H-benzo[5,6]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-
15(9H)-one (3Bc): Yield 82%; mp 206 ˝C; IR (KBr) νmax 1662, 1585 cm´1; 1H-NMR (CDCl3) 1.79–2.33
(m, H9, H10, H11, H12, H8), 2.92–2.99 (m, H13, 2H), 3.71 (s, OCH3, 3H), 5.87 (s, H16, 1H), 6.65 (d,
J = 7.8 Hz, H6, 1H), 6.84–7.49 (m, H2, H3, H21,H51, H61, H41, 6H), 7.80 (d, J = 8.4 Hz, H4,H5, 2H),
7.98 (d, J = 8.1 Hz, H1, 1H); 13C-NMR (CDCl3) 24.5 (CH, C10), 27.2 (CH, C11), 29.7 (CH, C12), 36.9
(CH, C16), 37.4 (CH, C9), 43.2 (CH, C13), 55.0 (OCH3), 101.0 (C, C15a), 111.6 (C, C41), 114.6 (CH, C21),
116.6 (CH, C5), 117.5 (CH, C61), 121.1 (C, C16a), 123.7 (CH, C1), 124.9 (CH, C3), 127.0 (CH, C2), 128.4
(CH, C6), 129.2 (CH, C4), 129.3 (C, C4a), 131.1 (CH, C51), 131.4 (C, C16b), 145.4 (C, C11), 148.1 (C, C6a),
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159.3 (C, C8a), 159.5 (C, C7a), 162.1 (C, C15), 163.5 (C, C31). Anal. Calcd. for C27H24N2O3: C, 76.40;
H, 5.70; N, 6.60. Found: C, 76.36; H, 5.73; N, 6.64.
14-(41-Methylphenyl)-10,11-dihydro-14H-benzo[5,6]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-13(9H)-one
(3Ca): Yield 82%; mp > 260 ˝C; IR (KBr) νmax 1661, 1594 cm´1; 1H-NMR (CDCl3) 1.21–1.25 (m,
H10, 2H), 2.2 (s, CH3, 3H), 3.06–3.12 (m, H9, 2H), 4.05–4.11 (m, H11, 2H), 5.90 (s, H14, 1H), 7.05 (d,
J = 8.7 Hz, H31, H51, 2H), 7.28–7.47 (m, H2, H3, H4, H5, H6, 5H), 7.81 (d, J = 8.7 Hz, H21, H61, 2H),7.97
d (d, J = 8.1 Hz, H1, 1H); 13C-NMR (CDCl3) 19.1 (CH2, C10), 20.9 (CH3), 32.4 (CH, C9), 36.0 (CH, C14),
47.0 (CH, C11), 101.5 (C, C13a), 116.7 (CH, C6), 117.5 (CH, C1), 123.7 (CH, C3), 124.8 (CH, C2), 127.0
(CH, C4), 128.3 (CH, C5), 128.4 (2CH, C21, C61), 129.0 (2CH, C31, C51), 129.2 (C, C14b), 131.1 (C, C14a),
131.5 (C, C4a), 136.2 (C, C41), 141.0 (C, C11), 148.2 (C, C6a), 161.1 (C, C8a), 161.4 (C, C7a), 162.4 (C, C13).
Anal. Calcd. for C25H20N2O2: C, 78.93; H, 5.30; N, 7.36. Found: C, 78.97; H, 5.27; N, 7.33.
15-(41-Methylphenyl)-10,11,12,15-tetrahydro-9H-benzo[5,6]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-14-one
(3Cb): Yield 94%; mp > 260 ˝C; IR (KBr) νmax 1658, 1586 cm´1; 1H-NMR (CDCl3) 1.83–1.88
(m, H10, 2H), 1.90–1.95 (m, H11, 2H), 2.22 (s, CH3, 3H), 2.92–2.96 (m, H9, 2H), 3.90–3.97 (m, H12,
2H), 5.86 (s, H15, 1H), 7.03 (d, J = 7.6 Hz, H31, H51, 2H), 7.28–7.48 (m, H2, H3,H4,H5,H6, 5H), 7.81
(d, J = 8.1 Hz, H21, H61, 2H), 7.96 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 19.0 (CH2, C10), 21.0
(CH3), 21.7 (CH, C11), 31.4 (CH, C9), 36.2 (CH, C15), 43.0 (CH, C12), 101.1 (C, C14a), 116.7 (CH, C6),
117.5 (CH, C1), 123.7 (CH, C3), 124.9 (CH, C2), 127.1 (CH, C4), 128.4 (CH, C5), 128.9 (2CH, C21, C61),
129.1 (2CH, C31, C51), 129.2 (C, C15b), 131.1 (C, C15a), 131.4 (C, C4a), 136.2 (C, C41), 141.0 (C, C11),
148.1 (C, C6a), 158.5 (C, C8a), 159.0 (C, C7a), 162.3 (C, C14). Anal. Calcd. for C26H22N2O2: C, 79.17;
H, 5.62; N, 7.10. Found: C, 79.12; H, 5.65; N, 7.14.
16-(4’-Methylphenyl)-10,11,12,13-tetrahydro-16H-benzo[5,6]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-15(9H)-one
(3Cc): Yield 86%; mp > 260 ˝C; IR (KBr) νmax 1659, 1589 cm´1; 1H-NMR (CDCl3) 1.82–2.04 (m, H9,
H10, H11, H12, 8H), 2.22 (s, 3H, CH3, 3H), 4.05–4.11 (m, H13, 2H), 5.86 (s, H16, 1H), 7.03 (d, J = 8.7 Hz,
H31, H51, 2H), 7.28–7.48 (m, H2, H3, H4, H5, H6, 5H), 7.80 (d, J = 9 Hz, H21,H61, 2H), 7.98 (d, J = 8.4 Hz,
H1, 1H); 13C-NMR (CDCl3) 21.0 (CH, C11), 24.5 (CH3), 27.2 (CH2, C10), 29.6 (CH, C12), 36.5 (CH, C9),
37.3 (CH, C16), 43.1 (CH, C13), 101.3 (C, C15a), 116.9 (CH, C6), 117.5 (CH, C1), 123.0 (CH, C3), 123.7
(CH, C2), 124.8 (CH, C4), 127.0 (CH, C5), 128.4 (2CH, C21, C61), 129.0 (2CH, C31, C51), 129.1 (C, C16b),
131.1 (C, C16a), 131.5 (C, C4a), 136.1 (C, C41), 141.0 (C, C11), 148.1 (C, C6a), 159.3 (C, C8a), 162.1
(C, C7a), 163.3 (C, C15). Anal. Calcd. for C27H24N2O2: C, 79.39; H, 5.92; N, 6.86. Found: C, 79.41;
H, 5.90; N, 6.89.
7-Phenyl-11,12-dihydro-7H-benzo[7,8]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-8(10H)-one (4Aa): Yield 79%;
mp > 260 ˝C; IR (KBr) νmax 1666, 1577 cm´1; 1H-NMR (CDCl3) 2.41–2.51 (m, 2H, H11), 3.07–3.17
(m, H12, 2H), 3.71–3.94 (m, H10, 2H), 5.31 (s, H7, 1H), 6.93–7.81 (m, H4, H2, H3, H5, H21, H51, H31,
H61, H41, H6, 10 H), 8.49 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 19.0 (CH2, C11), 32.5 (CH2, C12),
39.9 (CH, C7), 47.0 (CH2, C10), 100.2 (C, C7a), 118.6 (CH, C5), 121.6 (CH, C1), 123.8 (C, C6a), 124.7
(CH, C3), 126.4 (CH, C6), 126.5 (C, C14b), 126.8 (CH, C41), 127.5 (CH, C2), 128.4 (CH, C4), 128.5
(2CH, C31, C51), 129.1 (2CH, C21, C61), 144.6 (C, C11), 144.9 (C, C14a), 161.2 (C, C12a), 161.9 (C, C13a),
162.8 (C, C8). Anal. Calcd. for C24H18N2O2: C, 78.67; H, 4.95; N, 7.65. Found: C, 78.63; H, 4.97; N, 7.69.
7-Phenyl-10,11,12,13-tetrahydro-7H-benzo[7,8]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-8-one (4Ab): Yield 90%; mp
259 ˝C; IR (KBr) νmax 1667, 1572 cm´1; 1H-NMR (CDCl3) 1.92–1.94 (m, H10, 2H), 2.99–3.03 (m, H13,
2H), 3.88–3.91 (m, H11, H12, 4H), 5.33 (s, H7, 1H), 7.14–7.62 (m, H2, H3, H5, H21, H51, H31, H61, H41,
H6, 9H), 7.79 (d, J = 8.1 Hz, H4, 1H), 8.51 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 18.6 (CH2, C12),
21.3 (CH2, C11), 39.6 (CH, C7), 42.3 (CH2, C10), 45.2 (CH2, C13), 99.9 (C, C7a), 118.2 (CH, C5), 121.2
(CH, C1), 123.4 (C, C6a), 124.0 (CH, C3), 125.8 (CH, C6), 126.0 (C, C15b), 126.1 (CH, C41), 126.2 (CH,
C2), 127.0 (CH, C4), 127.9 (2CH, C21, C61), 128.1 (2CH, C31, C51), 132.7 (C, C4a), 144.1 (C, C11), 144.5 (C,
C15a), 158.2 (C, C13a), 162.0 (C, C14a), 177.3 (C, C8). Anal. Calcd. for C25H20N2O2: C, 78.93; H, 5.30;
N, 7.36. Found: C, 78.97; H, 5.27; N, 7.32.
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7-Phenyl-11,12,13,14-tetrahydro-7H-benzo[7,8]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-8(10H)-one (4Ac):
Yield 87%; mp 228 ˝C; IR (KBr) νmax 1659, 1589 cm´1; 1H-NMR (CDCl3) 1.76–1.87 (m, H14,H13,
H11, H12, 8H), 3.02–3.04 (m, H10, 2H), 5.34 (s, 1H, H7, 1H), 7.14–7.62 (m, H2, H3, H5, H21, H51, H31,
H61, H41, H6, 9H), 7.79 (d, J = 8.1 Hz, H4, 1H), 8.51 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 27.3
(CH, C13), 29.6 (CH2,C12), 30.5 (CH2, C11), 37.3 (CH2,C14), 40.4 (CH,C7), 43.0 (CH2,C10), 100.6 (C, C7a),
118.7 (CH, C5), 121.7 (CH, C1), 123.8 (C, C6a), 124.5 (CH, C3), 126.3 (CH, C6), 126.5 (C, C16b), 126.6
(CH, C41), 126.7 (CH, C2), 127.5 (CH, C4), 128.4 (2CH, C31, C51), 128.5 (2CH, C21, C61), 133.2
(C, C4a), 144.5(C, C11), 145.0 (C, C16a), 159.8 (C, C14a), 162.2 (C, C15a), 163.6 (C, C8). Anal. Calcd. for
C26H22N2O2: C, 79.17; H, 5.62; N, 7.10. Found: C, 79.12; H, 5.64; N, 7.15.
7-(31-Methoxyphenyl)-11,12-dihydro-7H-benzo[7,8]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-8(10H)-one (4Ba):
Yield 81%; mp 224 ˝C; IR (KBr) νmax 1663, 1577 cm´1; 1H-NMR (CDCl3) 2.22–2.27 (m, H11, 2H),
3.18–3.20 (m, H12, 2H), 3.74 (s, OCH3, 3H), 4.09–4.16 (m, H10, 2H), 5.36 (s, H7, 1H), 6.71 (d, J = 7.8 Hz,
H6, 1H), 6.91–7.60 (m, H2, H3, H5, H21, H51, H61, H41, 7H), 7.81 (d, J = 7.8 Hz, H4, 1H), 8.49 (d,
J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 19.1 (CH, C11), 32.5 (CH, C12), 39.9 (CH, C7), 47.0 (CH, C10),
55.1 (OCH3), 100.7 (C, C7a), 111.9 (CH, C41), 114.1 (CH, C21), 118.4 (CH, C5), 120.9 (CH, C61), 121.6
(C, C6a), 123.8 (CH, C1), 124.7 (C, C14b), 126.4 (CH, C3), 126.6 (2CH, C2, C6), 127.5 (CH, C4), 129.3
(CH, C51), 133.3 (C, C4a), 144.5 (C, C11), 146.5 (C, C14a), 159.6 (C, C12a), 161.1 (C, C13a), 161.8 (C, C8),
162.8 (C, C31). Anal. Calcd. for C25H20N2O3: C, 75.74; H, 5.09; N, 7.07. Found: C, 75.72; H, 5.11; N, 7.12.
7-(31-Methoxyphenyl)-10,11,12,13-tetrahydro-7H-benzo[7,8]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-8-one
(4Bb): Yield 90%; mp 238 ˝C; IR (KBr) νmax 1661, 1572 cm´1; 1H-NMR (CDCl3)1.89–1.94 (m, 4H, H11,
H12, 4H), 2.88–2.95 (m, H13, 2H), 3.71 (s, OCH3, 3H), 3.87–3.89 (m, H10, 2H), 5.31 (s, H7, 1H), 6.69 (d,
J = 8.1 Hz, H6, 1H), 6.89–7.59 (m, H2, H3, H5, H21, H51, H61, H41, 7H), 7.76 (d, J = 7.8 Hz, H4, 1H),
8.48 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 18.6 (CH, C12), 21.3 (CH, C11), 31.1 (CH,C13), 39.6
(CH, C7), 42.4 (CH, C10), 54.6 (OCH3), 99.7 (C, C7a), 111.3 (CH, C41), 114.1 (CH, C21), 118.1 (CH, C5),
120.5 (CH, C61), 121.2 (C, C6a), 123.4 (CH, C1), 124.0 (C, C15b), 125.8 (CH, C3), 126.0 (2CH, C2, C6),
127.0 (CH, C4), 128.8 (CH, C51), 132.7 (C, C4a), 143.9 (C, C11), 146.2 (C, C15a), 158.2 (C, C13a), 159.1
(C, C14a), 159.4 (C, C8), 162.0 (C, C31). Anal. Calcd. for C26H22N2O3: C, 76.08; H, 5.40; N, 6.82. Found:
C, 76.12; H, 5.37; N, 6.79.
7-(31-Methoxyphenyl)-11,12,13,14-tetrahydro-7H-benzo[7,8]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-8(10H)-one
(4Bc): Yield 79%; mp 215 ˝C; IR (KBr) νmax 1662, 1577 cm´1; 1H-NMR (CDCl3) 1.80–2.11 (m, H14, H11,
H13, H12, 8H), 3.10–3.17 (m, H10, 2H), 4.10 (s, OCH3, 3H), 5.29 (s, H7, 1H), 6.70 (d, J = 7.8 Hz, H6, 1H),
6.89–7.62 (m, H2, H3, H5, H21, H51, H61, H41, 7H), 7.79 (d, J = 7.8 Hz, H4, 1H), 8.51 (d, J = 8.1 Hz, H1,
1H); 13C-NMR (CDCl3) 24.0 (CH, C12), 26.7 (CH, C13), 29.1 (CH, C11), 36.4 (CH, C14), 39.8(CH, C7),
42.6 (CH, C10), 54.6 (OCH3), 100.0 (C, C7a), 111.4 (CH, C41), 114.1 (CH, C21), 118.0 (CH, C5), 120.5 (CH,
C61), 121.2 (C, C6a), 123.3 (CH, C1), 124.1 (C, C16b), 125.2 (CH, C3), 125.9 (2CH, C2,C6), 126.1 (CH, C4),
126.9 (CH, C51), 128.8 (C, C4a), 132.7 (C, C11), 143.8 (C, C16a), 146.0 (C, C14a), 159.1 (C, C15a), 161.4
(C, C8), 163.3 (C, C31). Anal. Calcd. for C27H24N2O3: C, 76.40; H, 5.70; N, 6.60. Found: C, 76.37;
H, 5.72; N, 6.63.
7-(41-Methylphenyl)-11,12-dihydro-7H-benzo[7,8]chromeno[2,3-d]pyrrolo[1,2-a]pyrimidin-8(10H)-one (4Ca):
Yield 78%; mp > 260 ˝C; IR (KBr) νmax 1661, 1589 cm´1; 1H-NMR (CDCl3) 2.14–2.21 (m, H11, 2H), 2.27
(s, CH3, 3H), 3.11–3.22 (m,H12, 2H), 4.05–4.12 (m, H10, 2H), 5.35 (s, H7, 1H), 7.06 (d, J = 7.8 Hz, H31,
H51, 2H), 7.17 (d, J = 8.7 Hz, H6, 1H), 7.25 (d, J= 7.8 Hz, H21, H61, 2H), 7.51–7.62 (m, H2, H3, H5, 3H),
7.72 (d, J = 8.4 Hz, H4, 1H) 8.49 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 19.11 (CH2, C11), 21.0 (CH3),
32.5 (CH2, C12), 39.5 (CH, C7), 46.9 (CH2, C10), 101.0 (C, C7a), 118.7 (CH, C5), 121.5 (CH, C1), 124.6
(C, C6a), 126.5 (CH, C3), 126.6 (CH, C6), 127.1 (CH, C2), 127.5 (C, C14b), 128.4 (CH, C4), 129.1
(2CH, C21, C61), 129.8 (2CH, C31, C51), 133.2 (C, C4a), 136.4 (C, C41), 142.1 (C, C11), 144.5 (C, C14a),
161.2 (C, C12a), 161.8 (C, C13a), 162.7 (C, C8). Anal. Calcd. for C25H20N2O2: C, 78.93; H, 5.30; N, 7.36.
Found: C, 78.97; H, 5.27; N, 7.38.
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7-(41-Methylphenyl)-10,11,12,13-tetrahydro-7H-benzo[7,8]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-8-one (4Cb):
Yield 86%; mp 224 ˝C; IR (KBr) νmax 1667, 1571 cm´1; 1H-NMR (CDCl3) 1.92–1.99 (m, H11,H12, 4H),
2.27 (s, CH3, 3H), 3.02–3.10 (m, H13, 2H), 3.90–3.96 (m, H10, 2H), 5.29 (s, H7, 1H), 7.06 (d, J = 7.8 Hz,
H31, H51, 2H), 7.14 (d, J = 8.1 Hz, H6, 1H), 7.23 (d, J = 7.8 Hz, H21, H61, 2H), 7.52–7.63 (m, H2, H3, H5,
3H), 7.79 (d, J = 7.8 Hz, H4, 1H), 8.52 (d, J = 8.4 Hz, H1, 1H); 13C-NMR (CDCl3) 18.9 (CH2, C12), 21.0
(CH3), 21.7 (CH2, C11), 31.2 (CH2, C13), 39.6 (CH, C7), 42.9 (CH2, C10), 100.6 (C, C7a), 118.7 (CH, C5),
123 (CH, C1), 124.7 (C, C6a), 126.5 (2CH, C3, C6), 127.0 (CH, C2), 127.5 (C, C15b), 127.8 (CH, C4), 128.4
(2CH, C21, C61), 129.1 (2CH, C31, C51), 133.2 (C, C4a), 136.4 (C, C41), 141.9 (C, C11), 144.3 (C, C15a),
158.9 (C, C13a), 159.1 (C, C14a), 162.1 (C, C8). Anal. Calcd. for C26H22N2O2: C, 79.17; H, 5.62; N, 7.10.
Found: C, 79.21; H, 5.59; N, 7.14.
17-(41-Methylphenyl)-11,12,13,14-tetrahydro-7H-benzo[7,8]chromeno[21,31,4,5]pyrimido[1,2-a]azepin-8(10H)-one
(4Cc): Yield 70%; mp > 260 ˝C; IR (KBr) νmax 1664, 1593 cm´1; 1H-NMR (CDCl3) 1.74–1.81 (m, H12,
2H), 1.85–1.96 (m, H11, H13, H14, 6H), 2.27 (s, CH3, 3H), 3.02–3.11 (m, H10, 2H), 5.30 (s, H7, 1H), 7.06
(d, J = 7.8 Hz, H31, H5, 2H1), 7.14 (d, J = 8.1 Hz, H6, 1H), 7.24 (d, J = 7.8 Hz, H21, H61, 2H), 7.50–7.62 (m,
H2, H3, H5, 3H), 7.70 (d, J = 7.8 Hz, H4, 1H), 7.79 (d, J = 8 Hz, H1, 1H); 13C-NMR (CDCl3) 21.0 (CH3),
24.6 (CH2, C12), 27.3 (CH2, C13), 29.6 (CH2,C11), 37.3 (CH2, C14), 40.0 (CH, C7), 43.0 (CH2, C10), 100.7
(C, C7a), 118.9 (CH, C5), 121.7 (CH, C1), 123.9 (C, C6a), 124.5 (CH, C3), 126.6 (CH, C6), 127.2 (C, C16b),
127.8 (CH, C4), 128.4 (2CH, C21, C61), 129.1 (2CH, C31,C51), 133.2 (C,C4a), 136.3 (C, C41), 142.2 (C, C11),
144.4 (C, C16a), 159.7 (C, C14a), 162.1 (C, C15a), 163.5 (C, C8). Anal. Calcd. For C27H24N2O2: C, 79.39;
H, 5.92; N, 6.86. Found: C, 79.35; H, 5.94; N, 6.89.
3.2. Oxygen Radical Absorbance Capacity Assay
The antioxidant power of BCPOs was determined following the ORAC-FL method using
fluorescein as the fluorescent probe [20,21]. (˘)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic
acid (Trolox), fluorescein (FL) and AAPH were bought from Sigma-Aldrich (Saint Louis, MO, USA). A
Varioskan Flash plate reader with built-in injectors (Thermo Scientific, Waltham, MA, USA) was used.
The final volume reaction mixture was 200 µL and the reaction was carried out at 37 ˝C in 75 mM
phosphate buffer (pH 7.4). The tested compounds and Trolox standard were dissolved in DMSO
to 10 mM and further diluted in phosphate buffer. The final concentrations were 0.1–1 µM for the
tested compounds and 1–8 µM for Trolox standard. The blank was composed of 120 µL of FL, 60 µL of
AAPH and 20 µL of phosphate buffer (pH = 7.4) and was added in each assay. The antioxidant (20 µL)
and fluorescein (FL, 120 µL, final concentration of 70 nM) were incubated in a black 96-well microplate
Nunc, purchazed from Thermo Fisher Scientific, Ecublens, Switzerland) for 15 min at 37 ˝C. Then,
AAPH, 60 µL, final concentration of 12 mM) solution was added quickly using the built-in injector.
The fluorescence decay was measured every minute for 60 min at λex = 485 nm and λem = 535 nm.
The microplate was automatically shaken prior to each reading. All the experiments were made in
triplicate and at least three different assays were performed for each sample. Antioxidant curves
(fluorescence versus time) were first normalized to the curve of the blank (without antioxidant) and
then, the area under the fluorescence decay curve (AUC) was calculated as:
AUC “ 1 ` sum pfi{f0q (1)
where f 0 is the initial fluorescence reading at 0 min and fi is the fluorescence value at time i. The net
AUC corresponding to the sample was calculated as follows:
Net AUC “ AUCantioxidant´AUCblank (2)
Using MS Excel software, regression equations were extrapolated by plotting the net AUC against
the antioxidant concentration. The ORAC values were then obtained by dividing the slope of the latter
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curve between the slope of the Trolox curve obtained in the same assay. Final ORAC values were
expressed as Trolox equivalents. Data are expressed as mean ˘ SD.
3.3. Inhibition of EeAChE and EqBuChE
Assessment of the inhibitory power of BCPOs was performed following the spectrophotometric
method of Ellman [23] using purified AChE from Electrophorus electricus (Type V-S, Sigma-Aldrich)
or BuChE from horse serum (lyophilized powder, Sigma-Aldrich). Enzymes were first dissolved in
0.1 M phosphate buffer (pH 8.0) and then aliquoted in small vials for easy handling. Compounds stock
solutions in DMSO (10 mM) were diluted when necessary with DMSO to prepare appropriate dilutions
of each compound. The assay was performed in a final volume of 3 mL of a 0.1 M phosphate-buffered
solution at pH 8.0, containing 5,51-dithiobis-2-nitrobenzoic acid (DTNB, 2625 µL, 0.35 mM, final
concentration), EeAChE (29 µL, 0.035 U/mL final concentration) or eqBuChE (60 µL, 0.05 U/mL final
concentration) tested compound (3 µL, different concentrations) and 1% (w/v) Bovine Albumin Serum
phosphate-buffered (pH 8.0) solution (BSA, 40 µL). The inhibition in comparison to control without
compound was determined by pre-incubating this blend at room temperature with each compound
at nine different concentrations for 10 min. Then, acetylthiocholine iodide (105 µL, 0.35 mM, final
concentration) or butyrylthiocholine iodide (150 µL, 0.5 mM final concentration) was added and
incubated for another 15 min at rt. The absorbances were measured at 412 nm in a plate reader
(iEMS Reader MF, Labsystems, Thermo fisher scientific Ecublens, Switzerland). The percentage of
inhibition of the enzyme was calculated in comparison with the blank sample (100% enzyme activity).
Calculation of IC50 values was performed with GraphPad Prism 5. Each concentration was measured
in triplicate. Data are expressed as mean ˘ SEM.
3.4. Inhibition of hAChE
Ellman’s assay was followed to evaluate the anticholinesterasic potency of BCPOs [23] using
human recombinant AChE (Sigma-Aldrich). 500 U of hAChE were dissolved in 1 mL of a gelatine
solution (1% in water) and diluted with demineralized water to give a stock solution of 5 U/mL.
The 12.5 mM 5,51-dithiobis-(2-nitrobenzoic acid) (DTNB, Ellman’s reagent) solution containing 0.15%
(w/v) sodium carbonate and 18.75 mM acetylthiocholine (ATC) iodide solution were prepared in
demineralized water. All assays were performed in 0.1 M phosphate buffer pH 8.0. The assayed
compounds or blank (water) (25 µL) were incubated with the enzyme (20 µL) for 5 min at 37 ˝C
in 765 µL of phosphate buffer prior to start the reaction. Then, 20 µL of DTNB and 20 µL of ATC were
added. After 5 min, absorbances were measured at 412 nm with an EnSpire Multimode microplate
reader (Perkin-Elmer, Waltham, MA, USA). The percentage of inhibition of the enzyme was calculated
by comparison with a blank sample (100% enzyme activity). IC50 values were determined with
GraphPad Prism 5. Each concentration was measured in triplicate. Data are expressed as mean ˘ SEM.
3.5. Kinetic Characterization of hAChE Inhibition
To estimate the type of inhibition of hAChE, we performed the same experimental protocol as
reported for hAChE inhibition. Different concentrations of the substrate ATC (0.067–0.5 mM) were used
to create Lineweaver-Burk plots by plotting the inverse initial velocity (1/V) as a function of the inverse
of the substrate concentration (1/[S]). The stock solution of ATC (0.5 mM in a well) was prepared in
demineralized water and diluted before use to obtain 0.4, 0.3, 0.2, 0.1 and 0.067 mM substrate solutions.
The double reciprocal plots were analysed by a weighted least square procedure that assumed the
variance of V to be constant. Each experiment was performed in triplicate. To confirm the mode of
inhibition, Cornish-Bowden plots were obtained by plotting S/V (substrate/velocity ratio) versus
the inhibitor concentration [23,28]. Data analysis was performed with GraphPad Prism 5. Inhibition
constant (Ki) values were determined by re-plotting slopes from the Lineweaver-Burk plot versus the
inhibitor concentration where Ki was determined as the intersect of the line with the x-axis [29].
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3.6. In vitro Toxicity of Compounds 3Ab, 3Bb, 3Cb and 3Ba in HepG2 Cells
HepG2 cells were purchased from American Type Culture Collection. The cells were cultured in
Eagle’s Minimum Essential Medium (Ozyme, France) supplemented with 10% fetal bovine serum, 1X
non-essential amino acids, 100 units/mL penicillin and 10 mg/mL streptomycin (Dutscher, Brumath,
France). Cultures were kept under a CO2/air (5%/95%) humidified atmosphere at 37 ˝C. Prior to the
experiment, cells were seeded in 96-well culture plates at a density of 0.1 ˆ 106 cells per well. After
24 h of incubation, the culture medium was refreshed and 100 µL of the test compounds or DMSO
(0.1%) were added. Compounds were tested at 4 concentrations (1–30 µM) in triplicate. For the MTT
assay [25], after 24 h of treatment, cells were incubated with 50 µL MTT (0.5 mg/mL, Sigma Aldrich,
city, France) at 37 ˝C for 2 h. Plates were centrifuged, MTT was removed and 100 µL DMSO was
distributed per well. The absorbance at 570 nm was measured using microplate reader (brand). Cell
viability was expressed as percentage of cell viability compared to controls (DMSO, 0.1%).
3.7. PAMPA Assay
Penetration across the BBB is an essential property for compounds targeting the CNS. In order to
predict passive blood-brain penetration of novel compounds modification of the PAMPA has been
used based on reported protocol [26,27]. The filter membrane of the donor plate was coated with
PBL (Polar Brain Lipid, Avanti, AL, USA) in dodecane (4 µL of 20 mg/mL PBL in dodecane) and the
acceptor well was filled with 300 µL of PBS pH 7.4 buffer (VD). Tested compounds were dissolved first
in DMSO and that diluted with PBS pH 7.4 to reach the final concentration 100 µM in the donor well.
Concentration of DMSO did not exceed 0.5% (v/v) in the donor solution. 300 µL of the donor solution
was added to the donor wells (VA) and the donor filter plate was carefully put on the acceptor plate so
that coated membrane was “in touch” with both donor solution and acceptor buffer. Test compound
diffused from the donor well through the lipid membrane (Area = 0.28 cm2) to the acceptor well. The
concentration of the drug in both donor and the acceptor wells was assessed after 3, 4, 5 and 6 h of
incubation in quadruplicate using the UV plate reader Synergy HT (Biotek, Winooski, VT, USA) at the
maximum absorption wavelength of each compound. Concentration of the compounds was calculated
















We have synthesized and evaluated eighteen new benzochromenopyrimidinones as promising
multitarget-directed ligands with marked selectivity for AChE and good antioxidant activity.
Particularly, compounds 3Ab, 3Bb, 3Cb and 3Ba were found to be non-hepatotoxic and moderate
hAChEIs. Among them, although compound 3Bb showed a Pe value in an uncertain interval
and consequently, a compromised permeability, this benzochromenopyrimidinone is a micromolar
mixed-type hAChE inhibitor (IC50 = 1.28 µM) and a potent antioxidant (4.7 TE). To sum up, this small
library of benzochromenopyrimidinones constitutes an additional step in our laboratory towards the
search for lead compounds with polypharmacological properties as potential new anti-AD agents.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/5/634/s1.
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